Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Cardiotonic Agents Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, the market size of cardiotonic agents has seen rapid expansion. The growth is set to continue, with the market expected to expand from $2.78 billion in 2024 to $3.11 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.9%. The historical period witnessed this growth due to several factors, including a rise in heart failure cases, an increase in the elderly population, a higher incidence of coronary artery disease, the adoption of more sedentary lifestyles, and the escalating burden of hypertension and diabetes.
There is a predicted sharp incline in the cardiotonic agents market size in the coming years, with an increase to $4.95 billion estimated by 2029 and a compound annual growth rate (CAGR) of 12.3%. The spike in size for the predicted time frame is contingent on factors such as the escalation in cardiovascular death rates, the increase in clinical trials tailored towards advancing cardiotonic formulations, enhanced cooperations between the public and private sector in cardiovascular drug invention, rising hospital admittance due to cardiac issues, and a heightened demand for individualized cardiovascular medicine. Some significant trends in the forecast period encompass the production of peptide-based cardiotonic agents, the creation of drugs with dual-mechanisms, the incorporation of pharmacogenomics, reinvention of injectable depot formulations, and introduction of combined therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp
Which Factors and External Forces Are Driving Demand in the Cardiotonic Agents Market?
The increase in cardiovascular disease incidence is anticipated to significantly drive the cardiotonic agents market’s expansion. Cardiovascular diseases, or CVDs, comprise various disorders impacting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmia, and stroke. These conditions are often attributable to unhealthy eating habits that are high in saturated and trans fats, salt, and additional sugars, leading to obesity, hypertension, and high cholesterol levels. By enhancing the efficacy and contraction potency of the heart muscle, cardiotonic agents aid in better blood flow and alleviate symptoms in multiple cardiovascular diseases. For example, doctor-certified deaths due to coronary heart disease (CHD) in Australia escalated from 14,100 cases in 2021 to 14,900 cases in 2022, as cited by the Australian Institute of Health and Welfare in December 2023. Hence, the cardiotonic agents market is experiencing growth due to the climbing rates of cardiovascular ailments.
Which Segments in the Cardiotonic Agents Offer the Most Growth?
The cardiotonic agents market covered in this report is segmented –
1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Dosage Form: Tablet, Solution, Other Dosage Forms
4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C
2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone
3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine
4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine
5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Cardiotonic Agents Market?# Market?
North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theCardiotonic Agents Market’s Growth?
Significant players in the cardiotonic agents market, such as Hikma Pharmaceuticals plc, are concentrating their efforts on the creation of innovative products like short-term inotropic drugs. These drugs are designed to boost cardiac performance in cases of acute heart failure or cardiogenic shock. Such drugs temporarily intensify the heart’s contraction power, leading to an improved cardiac output. In June 2023, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, introduced a Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is primarily used in adults suffering from cardiac decompensation due to a decrease in heart contractility, usually as a result of heart disease or post cardiac surgery. The injection, which functions by stimulating the beta-1 receptors, rapidly enhances heart muscle contraction and cardiac output (in just 1–2 minutes). Administered intravenously, the injection is generally given in a closely monitored hospital environment.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report
What Are the Key Elements That Define the Cardiotonic Agents Market?
Cardiotonic agents are a class of drugs that improve the efficiency and contraction of the heart muscle, improving its ability to pump blood. These agents are used to treat heart failure and certain arrhythmias by increasing cardiac output and improving circulation.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24184
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model